egaptivon pegol

An optimized, second-generation, PEGylated aptamer with antithrombotic property. Egaptivon pegol blocks the binding of von Willebrand factor (vWF), via the A1 domain, and ultra-large vWF multimers to platelets, as well as interferes with the binding of platelet receptor glycoprotein Ib, thus reducing platelet adhesion, aggregation and thrombus growth in arterial beds. Unlike other antiplatelet agents, this aptamer can be readily reversed by binding to a complementary sequence of oligonucleotides, and may therefore offer potential therapeutic benefit in surgery.